Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CYTOSORBENTS CORPORATION

(CTSO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CytoSorbents: Q1 Earnings Snapshot

05/04/2021 | 05:57pm EDT

MONMOUTH JUNCTION, N.J. (AP) _ CytoSorbents Corp. (CTSO) on Tuesday reported a loss of $4.2 million in its first quarter.

On a per-share basis, the Monmouth Junction, New Jersey-based company said it had a loss of 10 cents.

The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 3 cents per share.

The blood purification therapy company posted revenue of $10.6 million in the period, which also did not meet Street forecasts. Six analysts surveyed by Zacks expected $11.4 million.

CytoSorbents shares have risen 14% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $9.09, a decline of 3% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CTSO at https://www.zacks.com/ap/CTSO

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about CYTOSORBENTS CORPORATION
05/05CYTOSORBENTS CORP  : Results of Operations and Financial Condition (form 8-K)
AQ
05/04CYTOSORBENTS : Q1 Earnings Snapshot
AQ
05/04CYTOSORBENTS  : Earnings Flash (CTSO) CYTOSORBENTS CORPORATION Posts Q1 Loss $-0..
MT
05/04CYTOSORBENTS  : Earnings Flash (CTSO) CYTOSORBENTS CORPORATION Posts Q1 Revenue ..
MT
05/04CYTOSORBENTS  : Reports First Quarter 2021 Financial and Operational Results
PR
05/04CYTOSORBENTS  : Management's Discussion and Analysis of Financial Condition and ..
AQ
04/27CYTOSORBENTS  : to Report Q1 2021 Operating and Financial Results
PR
04/20CYTOSORBENTS CORP  : Other Events (form 8-K)
AQ
04/19CYTOSORBENTS  : Gets FDA's Conditional Approval to Start STAR-T Study For Blood ..
MT
04/19CYTOSORBENTS  : U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For..
PR
More news
Financials (USD)
Sales 2021 47,3 M - -
Net income 2021 -10,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -33,4x
Yield 2021 -
Capitalization 376 M 376 M -
Capi. / Sales 2021 7,96x
Capi. / Sales 2022 5,98x
Nbr of Employees 195
Free-Float 91,3%
Chart CYTOSORBENTS CORPORATION
Duration : Period :
Cytosorbents Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTOSORBENTS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 14,71 $
Last Close Price 8,69 $
Spread / Highest target 95,6%
Spread / Average Target 69,3%
Spread / Lowest Target 49,6%
EPS Revisions
Managers and Directors
NameTitle
Phillip P. Chan Chief Executive Officer & Director
Vincent J. Capponi President & Chief Operating Officer
Kathleen P. Bloch Chief Financial Officer & Secretary
Al W. Kraus Independent Non-Executive Chairman
Steven Sisk Director-Clinical Operations
Sector and Competitors